175 related articles for article (PubMed ID: 11136350)
21. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
[TBL] [Abstract][Full Text] [Related]
23. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
24. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.
Brod SA; Nelson LD; Khan M; Wolinsky JS
Int J Neurosci; 1997 Jun; 90(1-2):135-44. PubMed ID: 9285295
[TBL] [Abstract][Full Text] [Related]
25. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
[TBL] [Abstract][Full Text] [Related]
26. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
27. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects.
Goebel MU; Baase J; Pithan V; Exton M; Saller B; Schedlowski M; Limmroth V
Psychoneuroendocrinology; 2002 Nov; 27(8):881-92. PubMed ID: 12383450
[TBL] [Abstract][Full Text] [Related]
28. Role of interferons in demyelinating diseases.
Arnason BG; Toscas A; Dayal A; Qu Z; Noronha A
J Neural Transm Suppl; 1997; 49():117-23. PubMed ID: 9266421
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
30. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
van Boxel-Dezaire AH; van Trigt-Hoff SC; Killestein J; Schrijver HM; van Houwelingen JC; Polman CH; Nagelkerken L
Ann Neurol; 2000 Sep; 48(3):313-22. PubMed ID: 10976637
[TBL] [Abstract][Full Text] [Related]
31. Interferon-Beta Treatment Differentially Alters TLR2 and TLR4-Dependent Cytokine Production in Multiple Sclerosis Patients.
Oliveira IBN; Gomes RS; Gomides LF; Dos Santos JC; Carneiro MAD; Ribeiro-Dias F; Diniz DS
Neuroimmunomodulation; 2019; 26(2):77-83. PubMed ID: 30897575
[TBL] [Abstract][Full Text] [Related]
32. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS.
Chabot S; Yong VW
Neurology; 2000 Nov; 55(10):1497-505. PubMed ID: 11094104
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
34. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis.
Porrini AM; De Luca G; Gambi D; Reder AT
J Neuroimmunol; 1998 Jan; 81(1-2):109-15. PubMed ID: 9521612
[TBL] [Abstract][Full Text] [Related]
35. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients.
Porrini AM; Gambi D; Reder AT
J Neuroimmunol; 1995 Aug; 61(1):27-34. PubMed ID: 7560009
[TBL] [Abstract][Full Text] [Related]
36. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
[TBL] [Abstract][Full Text] [Related]
37. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS.
Sørensen TL; Sellebjerg F
Neurology; 2001 Oct; 57(8):1371-6. PubMed ID: 11673573
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
[TBL] [Abstract][Full Text] [Related]
39. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
Ersoy E; Kuş CN; Sener U; Coker I; Zorlu Y
Eur J Neurol; 2005 Mar; 12(3):208-11. PubMed ID: 15693810
[TBL] [Abstract][Full Text] [Related]
40. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
